Amoéba（0RAE）株式概要Amoéba S.A.はフランスで、水、健康、植物保護の分野における微生物学的リスク処理のための生物学的製品とサービスを開発している。 詳細0RAE ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長5/6過去の実績0/6財務の健全性2/6配当金0/6報酬当社が推定した公正価値より92.4%で取引されている 収益は年間62.74%増加すると予測されています リスク分析マイナスの株主資本 過去1年間で株主の希薄化は大幅に進んだ 収益が 100 万ドル未満 ( €695K )UK市場と比較した過去 3 か月間の株価の変動+1 さらなるリスクすべてのリスクチェックを見る0RAE Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.863.0k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-14m5m2016201920222025202620282031Revenue €4.8mEarnings €452.3kAdvancedSet Fair ValueView all narrativesAmoéba S.A. 競合他社SulNOx GroupSymbol: OFEX:SNOXMarket cap: UK£68.7mHardideSymbol: AIM:HDDMarket cap: UK£39.4mIofinaSymbol: AIM:IOFMarket cap: UK£92.1mZenova GroupSymbol: AIM:ZEDMarket cap: UK£780.1k価格と性能株価の高値、安値、推移の概要Amoéba過去の株価現在の株価€0.8652週高値€1.2352週安値€0.75ベータ0.221ヶ月の変化0%3ヶ月変化-7.53%1年変化-24.16%3年間の変化45.76%5年間の変化-54.81%IPOからの変化-95.90%最新ニュースお知らせ • Apr 16Amoéba and Koppert Highlight the Potential of Axpera Technology in Brazil for Strategic CropsAmoéba, industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, announces that it has conducted, in partnership with Koppert, an extensive programme of field trials in Brazil to assess the potential of its AXPERA biofungicide technology on several key crops, such as soya and orange trees, of which Brazil is the world’s leading producer. The visit, which took place at the end of March, demonstrated the promising results of the trials and confirmed the Brazilian market’s interest in Amoéba. With regard to soya, the trial programme conducted with several contractors in various production regions has confirmed the promising performance of AXPERA, under conditions of moderate to high pressure from Asian rust. These results are all the more remarkable given that AXPERA was tested under real-world farming conditions, as a complement to a standard fungicide programme and against a backdrop of high expectations among technicians for a multi-site biofungicide in the face of the growing risk of soybean rust resistance to chemical fungicides. As for orange trees, the initial results observed against bacterial canker appear encouraging and could, in the long term, help reduce the use of copper, given the known risks of bioaccumulation in the soil. These trials conducted in Brazil, which form part of the strategic agreement signed with Koppert in June 2025, thus confirm the full potential of AXPERA technology on crops such as soya and citrus, complementing the European and American markets where the two companies focus on vines and vegetable crops. On the strength of these initial results, Amoéba is considering the potential commercialisation of its technology in Brazil in 2028, once the following steps have been completed: Obtaining approval from the Brazilian authorities, a process falling under the remit of three ministries. The Ministry of Health has already confirmed that the AXPERA product poses no risk. The Ministries of the Environment and Agriculture are currently reviewing the product for its first targeted use against soya rust, with approval currently expected in 2027. Applications to extend the authorisation to new uses will then be submitted for strategic crops and diseases defined jointly with Koppert; Final confirmation of the marketing positioning following a new trial campaign to be carried out in 2027, in other regions representative of soya and orange cultivation.お知らせ • Mar 26Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million.Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,333,333 Price\Range: €0.75 Transaction Features: Subsequent Direct ListingNew Risk • Mar 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.5m free cash flow). Negative equity (-€14m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (€71.0m market cap, or US$83.9m).New Risk • Dec 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.5m free cash flow). Negative equity (-€14m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m (€682k revenue, or US$794k). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (€64.5m market cap, or US$75.0m).Breakeven Date Change • Sep 04Forecast to breakeven in 2027The 3 analysts covering Amoéba expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 15% per year to 2026. The company is expected to make a profit of €550.0k in 2027. Average annual earnings growth of 57% is required to achieve expected profit on schedule.New Risk • Jul 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 39% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.8m free cash flow). Negative equity (-€10m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m (€602k revenue, or US$696k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (€58.3m market cap, or US$67.4m).最新情報をもっと見るRecent updatesお知らせ • Apr 16Amoéba and Koppert Highlight the Potential of Axpera Technology in Brazil for Strategic CropsAmoéba, industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, announces that it has conducted, in partnership with Koppert, an extensive programme of field trials in Brazil to assess the potential of its AXPERA biofungicide technology on several key crops, such as soya and orange trees, of which Brazil is the world’s leading producer. The visit, which took place at the end of March, demonstrated the promising results of the trials and confirmed the Brazilian market’s interest in Amoéba. With regard to soya, the trial programme conducted with several contractors in various production regions has confirmed the promising performance of AXPERA, under conditions of moderate to high pressure from Asian rust. These results are all the more remarkable given that AXPERA was tested under real-world farming conditions, as a complement to a standard fungicide programme and against a backdrop of high expectations among technicians for a multi-site biofungicide in the face of the growing risk of soybean rust resistance to chemical fungicides. As for orange trees, the initial results observed against bacterial canker appear encouraging and could, in the long term, help reduce the use of copper, given the known risks of bioaccumulation in the soil. These trials conducted in Brazil, which form part of the strategic agreement signed with Koppert in June 2025, thus confirm the full potential of AXPERA technology on crops such as soya and citrus, complementing the European and American markets where the two companies focus on vines and vegetable crops. On the strength of these initial results, Amoéba is considering the potential commercialisation of its technology in Brazil in 2028, once the following steps have been completed: Obtaining approval from the Brazilian authorities, a process falling under the remit of three ministries. The Ministry of Health has already confirmed that the AXPERA product poses no risk. The Ministries of the Environment and Agriculture are currently reviewing the product for its first targeted use against soya rust, with approval currently expected in 2027. Applications to extend the authorisation to new uses will then be submitted for strategic crops and diseases defined jointly with Koppert; Final confirmation of the marketing positioning following a new trial campaign to be carried out in 2027, in other regions representative of soya and orange cultivation.お知らせ • Mar 26Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million.Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,333,333 Price\Range: €0.75 Transaction Features: Subsequent Direct ListingNew Risk • Mar 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.5m free cash flow). Negative equity (-€14m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (€71.0m market cap, or US$83.9m).New Risk • Dec 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.5m free cash flow). Negative equity (-€14m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m (€682k revenue, or US$794k). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (€64.5m market cap, or US$75.0m).Breakeven Date Change • Sep 04Forecast to breakeven in 2027The 3 analysts covering Amoéba expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 15% per year to 2026. The company is expected to make a profit of €550.0k in 2027. Average annual earnings growth of 57% is required to achieve expected profit on schedule.New Risk • Jul 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 39% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.8m free cash flow). Negative equity (-€10m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m (€602k revenue, or US$696k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (€58.3m market cap, or US$67.4m).Board Change • Jul 08High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. Director Valerie Filiatre is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • May 22Amoéba S.A., Annual General Meeting, Jun 26, 2025Amoéba S.A., Annual General Meeting, Jun 26, 2025. Location: 38 avenue des freres montgolfier, chassieu FranceNew Risk • Apr 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.8m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€10m). Revenue is less than US$1m (€602k revenue, or US$685k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Market cap is less than US$100m (€62.8m market cap, or US$71.4m).New Risk • Jun 06New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€3.9m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€13m free cash flow). Shares are highly illiquid. Negative equity (-€3.9m). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€5.8m net loss in 2 years). Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Market cap is less than US$100m (€24.3m market cap, or US$26.4m).お知らせ • May 25Amoéba S.A., Annual General Meeting, Jun 27, 2024Amoéba S.A., Annual General Meeting, Jun 27, 2024. Location: 38 avenue des freres montgolfier, chassieu FranceNew Risk • Sep 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Market cap is less than US$100m (€27.0m market cap, or US$28.7m).New Risk • Sep 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Market cap is less than US$100m (€28.4m market cap, or US$30.9m).Board Change • Apr 18Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Aug 17Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.株主還元0RAEGB ChemicalsGB 市場7D-6.4%5.8%2.5%1Y-24.2%8.7%19.4%株主還元を見る業界別リターン: 0RAE過去 1 年間で8.7 % の収益を上げたUK Chemicals業界を下回りました。リターン対市場: 0RAEは、過去 1 年間で19.4 % のリターンを上げたUK市場を下回りました。価格変動Is 0RAE's price volatile compared to industry and market?0RAE volatility0RAE Average Weekly Movement8.5%Chemicals Industry Average Movement7.9%Market Average Movement5.7%10% most volatile stocks in GB Market11.9%10% least volatile stocks in GB Market3.1%安定した株価: 0RAEの株価は、 UK市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 0RAEの weekly volatility ( 8% ) は過去 1 年間安定していますが、依然としてUKの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201023Jean-Francois Doucetamoeba-nature.comAmoéba S.A.は、フランスの水、健康、植物保護分野における微生物学的リスク処理のための生物学的製品とサービスを開発している。同社は、生きたアメーバWillaertia magna C2c Makyの天然の殺生物能力を利用した、水、表面、慢性創傷を処理する技術や、溶菌を利用した植物病原性微生物を処理する農業バイオコントロール技術を開発している。Amoéba S.A.は2010年に法人化され、フランスのシャシューに本社を置いている。もっと見るAmoéba S.A. 基礎のまとめAmoéba の収益と売上を時価総額と比較するとどうか。0RAE 基礎統計学時価総額€60.34m収益（TTM）-€8.30m売上高(TTM)€695.45k86.8xP/Sレシオ-7.3xPER（株価収益率0RAE は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0RAE 損益計算書（TTM）収益€695.45k売上原価€2.57m売上総利益-€1.87mその他の費用€6.43m収益-€8.30m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.12グロス・マージン-269.51%純利益率-1,193.86%有利子負債／自己資本比率-224.3%0RAE の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 18:19終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Amoéba S.A. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Andrew KeenEdison Investment ResearchGuy SipsKBC Securities NVThomas VrankenKBC Securities NV3 その他のアナリストを表示
お知らせ • Apr 16Amoéba and Koppert Highlight the Potential of Axpera Technology in Brazil for Strategic CropsAmoéba, industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, announces that it has conducted, in partnership with Koppert, an extensive programme of field trials in Brazil to assess the potential of its AXPERA biofungicide technology on several key crops, such as soya and orange trees, of which Brazil is the world’s leading producer. The visit, which took place at the end of March, demonstrated the promising results of the trials and confirmed the Brazilian market’s interest in Amoéba. With regard to soya, the trial programme conducted with several contractors in various production regions has confirmed the promising performance of AXPERA, under conditions of moderate to high pressure from Asian rust. These results are all the more remarkable given that AXPERA was tested under real-world farming conditions, as a complement to a standard fungicide programme and against a backdrop of high expectations among technicians for a multi-site biofungicide in the face of the growing risk of soybean rust resistance to chemical fungicides. As for orange trees, the initial results observed against bacterial canker appear encouraging and could, in the long term, help reduce the use of copper, given the known risks of bioaccumulation in the soil. These trials conducted in Brazil, which form part of the strategic agreement signed with Koppert in June 2025, thus confirm the full potential of AXPERA technology on crops such as soya and citrus, complementing the European and American markets where the two companies focus on vines and vegetable crops. On the strength of these initial results, Amoéba is considering the potential commercialisation of its technology in Brazil in 2028, once the following steps have been completed: Obtaining approval from the Brazilian authorities, a process falling under the remit of three ministries. The Ministry of Health has already confirmed that the AXPERA product poses no risk. The Ministries of the Environment and Agriculture are currently reviewing the product for its first targeted use against soya rust, with approval currently expected in 2027. Applications to extend the authorisation to new uses will then be submitted for strategic crops and diseases defined jointly with Koppert; Final confirmation of the marketing positioning following a new trial campaign to be carried out in 2027, in other regions representative of soya and orange cultivation.
お知らせ • Mar 26Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million.Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,333,333 Price\Range: €0.75 Transaction Features: Subsequent Direct Listing
New Risk • Mar 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.5m free cash flow). Negative equity (-€14m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (€71.0m market cap, or US$83.9m).
New Risk • Dec 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.5m free cash flow). Negative equity (-€14m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m (€682k revenue, or US$794k). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (€64.5m market cap, or US$75.0m).
Breakeven Date Change • Sep 04Forecast to breakeven in 2027The 3 analysts covering Amoéba expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 15% per year to 2026. The company is expected to make a profit of €550.0k in 2027. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
New Risk • Jul 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 39% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.8m free cash flow). Negative equity (-€10m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m (€602k revenue, or US$696k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (€58.3m market cap, or US$67.4m).
お知らせ • Apr 16Amoéba and Koppert Highlight the Potential of Axpera Technology in Brazil for Strategic CropsAmoéba, industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, announces that it has conducted, in partnership with Koppert, an extensive programme of field trials in Brazil to assess the potential of its AXPERA biofungicide technology on several key crops, such as soya and orange trees, of which Brazil is the world’s leading producer. The visit, which took place at the end of March, demonstrated the promising results of the trials and confirmed the Brazilian market’s interest in Amoéba. With regard to soya, the trial programme conducted with several contractors in various production regions has confirmed the promising performance of AXPERA, under conditions of moderate to high pressure from Asian rust. These results are all the more remarkable given that AXPERA was tested under real-world farming conditions, as a complement to a standard fungicide programme and against a backdrop of high expectations among technicians for a multi-site biofungicide in the face of the growing risk of soybean rust resistance to chemical fungicides. As for orange trees, the initial results observed against bacterial canker appear encouraging and could, in the long term, help reduce the use of copper, given the known risks of bioaccumulation in the soil. These trials conducted in Brazil, which form part of the strategic agreement signed with Koppert in June 2025, thus confirm the full potential of AXPERA technology on crops such as soya and citrus, complementing the European and American markets where the two companies focus on vines and vegetable crops. On the strength of these initial results, Amoéba is considering the potential commercialisation of its technology in Brazil in 2028, once the following steps have been completed: Obtaining approval from the Brazilian authorities, a process falling under the remit of three ministries. The Ministry of Health has already confirmed that the AXPERA product poses no risk. The Ministries of the Environment and Agriculture are currently reviewing the product for its first targeted use against soya rust, with approval currently expected in 2027. Applications to extend the authorisation to new uses will then be submitted for strategic crops and diseases defined jointly with Koppert; Final confirmation of the marketing positioning following a new trial campaign to be carried out in 2027, in other regions representative of soya and orange cultivation.
お知らせ • Mar 26Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million.Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,333,333 Price\Range: €0.75 Transaction Features: Subsequent Direct Listing
New Risk • Mar 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.5m free cash flow). Negative equity (-€14m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (€71.0m market cap, or US$83.9m).
New Risk • Dec 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.5m free cash flow). Negative equity (-€14m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m (€682k revenue, or US$794k). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (€64.5m market cap, or US$75.0m).
Breakeven Date Change • Sep 04Forecast to breakeven in 2027The 3 analysts covering Amoéba expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 15% per year to 2026. The company is expected to make a profit of €550.0k in 2027. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
New Risk • Jul 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 39% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.8m free cash flow). Negative equity (-€10m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m (€602k revenue, or US$696k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (€58.3m market cap, or US$67.4m).
Board Change • Jul 08High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. Director Valerie Filiatre is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • May 22Amoéba S.A., Annual General Meeting, Jun 26, 2025Amoéba S.A., Annual General Meeting, Jun 26, 2025. Location: 38 avenue des freres montgolfier, chassieu France
New Risk • Apr 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.8m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€10m). Revenue is less than US$1m (€602k revenue, or US$685k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Market cap is less than US$100m (€62.8m market cap, or US$71.4m).
New Risk • Jun 06New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€3.9m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€13m free cash flow). Shares are highly illiquid. Negative equity (-€3.9m). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€5.8m net loss in 2 years). Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Market cap is less than US$100m (€24.3m market cap, or US$26.4m).
お知らせ • May 25Amoéba S.A., Annual General Meeting, Jun 27, 2024Amoéba S.A., Annual General Meeting, Jun 27, 2024. Location: 38 avenue des freres montgolfier, chassieu France
New Risk • Sep 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Market cap is less than US$100m (€27.0m market cap, or US$28.7m).
New Risk • Sep 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Market cap is less than US$100m (€28.4m market cap, or US$30.9m).
Board Change • Apr 18Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Aug 17Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
